New alternatives and strategies in the treatment of inhibitors.
It is clear that the challenge of factor VIII and factor IX inhibitors requires a multi-faceted approach. The emphasis on new data at this symposium has indicated that there are a number of ideas that are ready for laboratory and clinical testing. These opportunities will be explored as new approaches are considered for the identification of hemophiliacs at risk of inhibitor formation, the modification of the immune response in inhibitor patients and the treatment of inhibitor patients in a way that achieves more satisfactory hemostasis.
D000941:Antigens / Q000032:analysis; D001323:Autoantibodies; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001803:Blood Transfusion; D005164:Factor IX / Q000276:immunology*; D005169:Factor VIII / Q000032:analysis / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006801:Humans
D000941:Antigens; D001323:Autoantibodies; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX